These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7931648)

  • 1. Clinical use of octreotide in unresectable meningiomas. A report of three cases.
    García-Luna PP; Relimpio F; Pumar A; Pereira JL; Leal-Cerro A; Trujillo F; Cortés A; Astorga R
    J Neurosurg Sci; 1993 Dec; 37(4):237-41. PubMed ID: 7931648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of unresectable skull base meningiomas with somatostatin analogs.
    Schulz C; Mathieu R; Kunz U; Mauer UM
    Neurosurg Focus; 2011 May; 30(5):E11. PubMed ID: 21529167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy.
    Simó M; Argyriou AA; Macià M; Plans G; Majós C; Vidal N; Gil M; Bruna J
    Cancer Chemother Pharmacol; 2014 May; 73(5):919-23. PubMed ID: 24619496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue.
    Chamberlain MC; Glantz MJ; Fadul CE
    Neurology; 2007 Sep; 69(10):969-73. PubMed ID: 17785665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma.
    Mason WP; Gentili F; Macdonald DR; Hariharan S; Cruz CR; Abrey LE
    J Neurosurg; 2002 Aug; 97(2):341-6. PubMed ID: 12186462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma.
    Johnson DR; Kimmel DW; Burch PA; Cascino TL; Giannini C; Wu W; Buckner JC
    Neuro Oncol; 2011 May; 13(5):530-5. PubMed ID: 21558077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visual improvement during octreotide therapy in a case of episellar meningioma.
    Jaffrain-Rea ML; Minniti G; Santoro A; Bastianello S; Tamburrano G; Gulino A; Cantore G
    Clin Neurol Neurosurg; 1998 Mar; 100(1):40-3. PubMed ID: 9637203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
    Norden AD; Ligon KL; Hammond SN; Muzikansky A; Reardon DA; Kaley TJ; Batchelor TT; Plotkin SR; Raizer JJ; Wong ET; Drappatz J; Lesser GJ; Haidar S; Beroukhim R; Lee EQ; Doherty L; Lafrankie D; Gaffey SC; Gerard M; Smith KH; McCluskey C; Phuphanich S; Wen PY
    Neurology; 2015 Jan; 84(3):280-6. PubMed ID: 25527270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway.
    Schrell UM; Rittig MG; Anders M; Kiesewetter F; Marschalek R; Koch UH; Fahlbusch R
    J Neurosurg; 1997 May; 86(5):845-52. PubMed ID: 9126901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review.
    Graillon T; Romano D; Defilles C; Saveanu A; Mohamed A; Figarella-Branger D; Roche PH; Fuentes S; Chinot O; Dufour H; Barlier A
    J Neurosurg; 2017 Sep; 127(3):660-669. PubMed ID: 27982767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.
    Schrell UM; Rittig MG; Anders M; Koch UH; Marschalek R; Kiesewetter F; Fahlbusch R
    J Neurosurg; 1997 May; 86(5):840-4. PubMed ID: 9126900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin inhibits the activity of adenylate cyclase in cultured human meningioma cells and stimulates their growth.
    Koper JW; Markstein R; Kohler C; Kwekkeboom DJ; Avezaat CJ; Lamberts SW; Reubi JC
    J Clin Endocrinol Metab; 1992 Mar; 74(3):543-7. PubMed ID: 1346787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone.
    Grunberg SM; Weiss MH; Spitz IM; Ahmadi J; Sadun A; Russell CA; Lucci L; Stevenson LL
    J Neurosurg; 1991 Jun; 74(6):861-6. PubMed ID: 2033444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of meningioma with octreotide.
    Rünzi MW; Jaspers C; Windeck R; Benker G; Mehdorn HM; Reinhardt V; Reinwein D
    Lancet; 1989 May; 1(8646):1074. PubMed ID: 2566017
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of meningioma with octreotide.
    Rünzi MW; Jaspers C; Windeck R; Benker G; Mehdorn M; Reinhardt V; Reinwein D
    Lancet; 1989 Jul; 2(8656):217-8. PubMed ID: 2568544
    [No Abstract]   [Full Text] [Related]  

  • 16. Anaplastic meningioma: octreotide therapy for a case of recurrent and progressive intracranial disease.
    Rammo R; Rock A; Transou A; Raghunathan A; Rock J
    J Neurosurg; 2016 Feb; 124(2):496-500. PubMed ID: 26274993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hydroxyurea treatment for unresectable meningioma].
    Fuentes S; Chinot O; Dufour H; Paz-Paredes A; Métellus P; Barrie-Attarian M; Grisoli F
    Neurochirurgie; 2004 Sep; 50(4):461-7. PubMed ID: 15547484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcium channel antagonists augment hydroxyurea- and ru486-induced inhibition of meningioma growth in vivo and in vitro.
    Ragel BT; Gillespie DL; Kushnir V; Polevaya N; Kelly D; Jensen RL
    Neurosurgery; 2006 Nov; 59(5):1109-20; discussion 1120-1. PubMed ID: 17143245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of chemotherapy and targeted therapy in the treatment of intracranial meningioma.
    Chamberlain MC
    Curr Opin Oncol; 2012 Nov; 24(6):666-71. PubMed ID: 22759739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma.
    Grunberg SM; Weiss MH; Russell CA; Spitz IM; Ahmadi J; Sadun A; Sitruk-Ware R
    Cancer Invest; 2006 Dec; 24(8):727-33. PubMed ID: 17162554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.